Peptides are short chains of amino acids, the same building blocks that make up proteins. Over the last decade, researchers have found that carefully designed peptide molecules can interact with receptors and enzymes in highly specific ways, making them attractive subjects for pharmaceutical research across a striking range of conditions. That growing interest has created a practical problem: the standard laboratory methods for assembling peptides are slow, expensive, and generate a lot of chemical waste.
A paper published in the Journal of the American Chemical Society describes a new platform that addresses several of those limitations at once. The researchers combined an existing but constrained technique called tag-assisted peptide synthesis with a newly developed ligation step they call aryl selenoester aminolysis ligation, abbreviated ASAL. The result, they report, is a more efficient and environmentally friendlier route to building the kinds of long, complex peptides that are most relevant to pharmaceutical research.
To demonstrate the method, the team synthesized three peptides of increasing complexity, including chains as long as 39 amino acid residues. Understanding why that matters requires a short look at how peptide synthesis currently works and where it tends to break down.
The standard synthesis problem
The dominant laboratory technique for building peptides is called solid-phase peptide synthesis, or SPPS. In SPPS, amino acids are added one at a time to a growing chain that is anchored to a solid resin bead. The method is reliable for short peptides, roughly up to 20 amino acid residues, but it becomes increasingly problematic as chains get longer. Errors accumulate, yields drop, purification becomes harder, and the volumes of solvent and reagent required grow substantially.
For longer peptide targets, chemists often turn to fragment condensation, in which separately built short segments are joined together using chemical coupling reagents. This approach can reach longer chain lengths, but it introduces a different hazard: epimerization. Epimerization is a subtle structural scrambling in which the three-dimensional arrangement of atoms around a single carbon flips into its mirror image. Even a small amount of epimerization produces a peptide that looks nearly identical on paper but behaves differently in a biological system, which is a serious quality concern for any research compound.
Tag-assisted synthesis and its ceiling
Tag-assisted peptide synthesis, or TAPS, was developed as a more sustainable alternative to SPPS. Rather than anchoring the growing chain to a solid support, TAPS uses a soluble chemical tag that keeps the peptide in solution and makes purification easier. The approach cuts down on solvent waste and simplifies several steps in the workflow.
The limitation, as the authors point out, is length. TAPS works well for peptides up to about 20 residues. Beyond that, the methodology becomes unreliable, which happens to be precisely the range where many pharmaceutically interesting peptides live. Glucagon-related hormones, parathyroid hormone fragments, and other signaling peptides often run between 25 and 45 residues. A method that tops out at 20 can handle research tools, but it cannot reliably build the more complex targets that drive drug discovery pipelines.
The ASAL ligation approach
The core innovation reported in the paper is a ligation chemistry built around a class of compounds called aryl selenoesters. A selenoester is a chemical group that, when set up correctly, can react with the free amino end of another peptide fragment in a process called aminolysis. The reaction joins two fragments together at a peptide bond without requiring the harsh coupling reagents that cause epimerization in classical fragment condensation.
The researchers showed that peptide fragments generated through TAPS can be converted into aryl selenoester intermediates and then ligated to other TAPS-derived fragments in a single, controlled reaction. Because the ASAL step does not rely on the same coupling chemistry that scrambles stereochemistry, the researchers report minimal epimerization in their products. The two methods, TAPS and ASAL, are described as complementary: TAPS handles the assembly of individual short fragments, and ASAL stitches those fragments into longer chains.
The environmental angle is also explicitly addressed in the paper. The combined workflow uses fewer reagents and smaller solvent volumes than either classical SPPS or fragment condensation. The authors frame this as an advantage not only for cost but for the broader goal of making pharmaceutical manufacturing more sustainable.
Three demonstration peptides
To validate the platform, the team applied it to three therapeutically relevant peptides of increasing structural complexity. The first was teriparatide, a 34-residue fragment of human parathyroid hormone that is used clinically in osteoporosis treatment. The second was a 32-residue sulfated peptide derived from the tsetse fly that functions as a thrombin inhibitor with anticoagulant properties. The third was tirzepatide, a 39-residue dual-receptor agonist that has been studied for glycemic control and weight management in type 2 diabetes research.
These three molecules were chosen deliberately. Each one sits well above the 20-residue ceiling that limits standard TAPS, and each represents a different structural challenge. Teriparatide tests the method on a clinically established peptide hormone. The tsetse fly-derived anticoagulant introduces sulfated amino acids, which are chemically demanding modifications. Tirzepatide, the longest of the three at 39 residues, includes a fatty acid modification that complicates purification and handling.
The successful convergent synthesis of all three, the researchers report, demonstrates that the ASAL platform can be applied across a meaningful range of structural types and chain lengths.
What convergent synthesis means in practice
The term convergent synthesis refers to a strategy in which multiple fragments are built in parallel and then assembled together, as opposed to a linear approach where each amino acid is added one at a time in sequence. Convergence is attractive for scalability. If a 39-residue peptide is divided into three 13-residue fragments, those fragments can be synthesized simultaneously and then joined. This compresses the total time and reduces the risk that an early error propagates through an entire long chain.
The TAPS plus ASAL workflow is described as inherently convergent. Each fragment is assembled and purified independently using TAPS, converted to its selenoester form, and then ligated in a defined order. The authors suggest this architecture makes the platform scalable not just in the laboratory setting but potentially in industrial manufacturing, where batch size, throughput, and consistency all matter significantly.
Relevance to the research peptide field
For anyone interested in research peptides, the significance of this paper is mostly upstream of the compounds themselves. How a peptide is made determines a great deal about its final quality. A synthesis route that minimizes epimerization produces a compound whose stereochemical identity matches the target sequence more reliably. A route that reduces solvent and reagent use can, in principle, lower the cost of producing high-purity material at scale.
The literature has long recognized that peptide purity is one of the most important variables in research settings. A compound with substantial levels of epimeric byproducts or incomplete ligation fragments will produce different experimental results than a highly pure preparation of the same sequence. Methods that structurally improve the synthesis process are therefore relevant not just to manufacturers but to researchers who depend on consistent, well-characterized starting material.
Early data from this study points at ASAL as a promising addition to the synthetic chemistry toolkit, though the authors frame their results as a demonstration platform rather than a fully commercialized process. Further work will be needed to establish how the method performs across a broader library of sequences and under industrial production conditions.
